Bimatoprost against latanoprost in blurred intraocular burden in glaucoma and ocular hypertension

This analysis evaluated the analytic affirmation of the allusive ability and assurance of bimatoprost and latanoprost in blurred intraocular burden (IOP) in patients with glaucoma and ocular hypertension. Four head-to-head, randomized, and controlled analytic trials of bimatoprost and latanoprost with analysis periods alignment from 1 to 6 months were articular from searches of the MEDLINE database through February 2004.
According to a analysis and allegory of the results, bimatoprost, if compared with latanoprost, was associated with greater beggarly reductions in IOP, greater beggarly increases in the allotment of patients demonstrating ambition IOP, and greater acknowledgment rates. The differences amid drugs were not consistently statistically significant. Overall, the between-group differences in beggarly IOP ranged from 0 to 1.5 mm Hg. In 92% of the IOP measurements, the beggarly IOP was lower a part of patients accustomed bimatoprost than a part of those accustomed latanoprost; in the actual 8%, the IOP abridgement was equal. Transient, balmy conjunctival hyperemia was the a lot of frequently appear adverse aftereffect associated with either drug, but it occurred added frequently with bimatoprost.
Overall, both drugs were able-bodied tolerated. As a 1-mm Hg change in IOP has been apparent to abate the accident of progression in patients with glaucoma (according to the Early Manifest Glaucoma Trial), the greater ability approved by bimatoprost in blurred IOP may be clinically significant.